drugset / Trial / NCT02535156

Schizotypal Personality Disorder Risperidone

NCT02535156

Phase 1/2 Completed 21 enrolled Sant Pau Research Institute
Non-randomizedCrossoverDouble-blindBasic science

Summary

Neurophysiological indices of self-monitoring were assessed in a group of patients with Schizotypal Personality Disorder (SPD) and a control group. Both groups were assessed after the administration of risperidone and placebo.

Timeline

Start
2003-01
Primary completion
2014-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 1 mg